Yujin has been selected to join the 2026 Global Bridge Training Program: Translational Research Commercialization Track, organized by the Ministry of Health and Welfare and the Korea Health Industry Development Institute (KHIDI). The four-week Basel Translational Innovation Program (BTIP) of KHIDI will take place in Basel, Switzerland, throughout November.

The program is designed to foster future physician-scientists with the capacity to translate research outcomes into technologies and industries applicable in real-world healthcare settings. Twelve early-career researchers and physician-scientists in translational medicine were selected from across Korea. During the program, Yujin will engage with Basel’s innovation ecosystem, including the University of Basel, University Hospital Basel, global pharmaceutical companies such as Roche and Novartis, biotech and medtech startups, and technology transfer offices.

Through the program, Yujin aims to gain a deeper understanding of how AI- and data-driven biomedical research can address unmet clinical needs and translate into real-world healthcare and industry. She will particularly explore translational research cases and strategies for intellectual property, technology transfer, and commercialization to further define the clinical and societal potential of her research.